Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Tycel Jovelle Phillips"'
Publikováno v:
Annals of Lymphoma. 6:12-12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3f554530db291f46c4c55a124e0ee95
https://doi.org/10.21037/aol-22-8
https://doi.org/10.21037/aol-22-8
Autor:
Franck Morschhauser, Yanwen Jiang, Fabrice Jardin, Alex Francisco Herrera, Laurie Helen Sehn, Charles Herbaux, Christopher Flowers, Tycel Jovelle Phillips, Armando López Guillermo, Catherine S. Magid Diefenbach, Gareth Gregory, Austin Injae Kim, Anna Maria Barbui, Sandhya Balasubramanian, Will Harris, Jamie Hirata, Joseph N. Paulson, Calvin Lee, Georg Lenz
Publikováno v:
Journal of Clinical Oncology. 40:7517-7517
7517 Background: Overexpression of BCL2 and MYC, and translocation of MYC, BCL2, and BCL6, are associated with poorer outcomes in patients (pts) with DLBCL (Horn et al. Blood 2013). We previously reported progression-free survival (PFS) from POLARIX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea8d63f5fe0379ae66e46e66ea7d3991
https://doi.org/10.1200/jco.2022.40.16_suppl.7517
https://doi.org/10.1200/jco.2022.40.16_suppl.7517
Autor:
Joshua Brody, Bjorn E. Wahlin, Tycel Jovelle Phillips, Régis Costello, Pieternella Lugtenburg, Raul Cordoba, Liwei Wang, Jun Wu, Brian Elliott, Aqeel Abbas, Judit Jørgensen
Publikováno v:
Journal of Clinical Oncology. 40:7527-7527
7527 Background: Pts with R/R DLBCL who fail or are ineligible for ASCT have very poor outcomes with standard palliative chemotherapy. Rituximab + GemOx had a complete response rate of 33% (Cazelles et al, Leuk Lymphoma 2021); novel approaches are ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e923058b9e0082134336c7da4309dfa
https://doi.org/10.1200/jco.2022.40.16_suppl.7527
https://doi.org/10.1200/jco.2022.40.16_suppl.7527
Autor:
Pau Abrisqueta, Lorenzo Falchi, Tycel Jovelle Phillips, Sven De Vos, Marcel Nijland, Fritz Offner, Irina Bykhovski, Jun Wu, Liwei Wang, Ali Rana, Raul Cordoba
Publikováno v:
Journal of Clinical Oncology. 40:7528-7528
7528 Background: Current standard of care for pts with R/R DLBCL eligible for ASCT includes salvage immunochemotherapy, such as rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin (R-DHAX/C), followed by consolidation with high-dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2337f4f535764708590f9ae9f6728bc
https://doi.org/10.1200/jco.2022.40.16_suppl.7528
https://doi.org/10.1200/jco.2022.40.16_suppl.7528
Autor:
Connie Lee Batlevi, Steven I. Park, Tycel Jovelle Phillips, Jennifer Amengual, David Jacob Andorsky, Philip Campbell, Pamela McKay, John Paul Leonard, Manu Sondhi, Jay Yang, Yingxue Chen, Heather O'Connor, Pamela Slatcher, Franck Morschhauser
Publikováno v:
Journal of Clinical Oncology. 40:7572-7572
7572 Background: Tazemetostat (TAZ), an enhancer of zeste homolog 2 (EZH2) inhibitor, showed antitumor activity as monotherapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL) who received ≥2 prior lines of therapy. In clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62a20104ec48c78e30ac9d77cca44563
https://doi.org/10.1200/jco.2022.40.16_suppl.7572
https://doi.org/10.1200/jco.2022.40.16_suppl.7572
Autor:
Radhika Takiar, Philip S. Boonstra, Yasmin Karimi, Shannon Carty, Ryan A. Wilcox, Tycel Jovelle Phillips
Publikováno v:
Journal of Clinical Oncology. 40:e19570-e19570
e19570 Background: Despite novel therapies for relapsed/refractory (R/R) DLBCL, outcomes among this cohort remain poor. A prior study indicated that patients who lost CD20 expression after treatment have earlier disease progression, but whether this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e07951c2c8770d0896e42e49f85dea3c
https://doi.org/10.1200/jco.2022.40.16_suppl.e19570
https://doi.org/10.1200/jco.2022.40.16_suppl.e19570
Autor:
Andrew David Zelenetz, Wojciech Jurczak, Vincent Ribrag, Kim Linton, Graham P. Collins, Javier López-Jiménez, Nishitha Reddy, Andrea Mengarelli, Tycel Jovelle Phillips, Gerardo Musuraca, Oonagh Sheehy, Joanne Li, Weiming Xu, Michel Meyer Azoulay, Richard Ghalie, Pier Luigi Zinzani
Publikováno v:
Journal of Clinical Oncology. 40:7511-7511
7511 Background: Zandelisib, a PI3Kδ inhibitor with high target-binding affinity, is administered by intermittent dosing (ID) on days 1-7 of 28-day cycles to potentially enable regulatory T-cell repopulation and lower the risk of immune adverse even
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77495d72f514a67d5d91f53708dbd45a
https://doi.org/10.1200/jco.2022.40.16_suppl.7511
https://doi.org/10.1200/jco.2022.40.16_suppl.7511
Autor:
Barbara Yim, Arthur T. Evans, Susan McDunn, Thomas E. Lad, Tareq Braik, Mohammed A. Kassem, Tycel Jovelle Phillips, Lily Hussein, Michael Russell Mullane, Barbara Cleveland
Publikováno v:
Journal of Clinical Oncology. 30:9085-9085
9085 Background: Capecitabine is an oral fluoropyrimidine that is used to treat various malignancies. Hand and Foot Syndrome (HFS) is a dose limiting toxicity of capecitabine and can limit the use of this agent in some patients. Some investigators ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfdc3fc922971a1f8f75678c39b5827d
https://doi.org/10.1200/jco.2012.30.15_suppl.9085
https://doi.org/10.1200/jco.2012.30.15_suppl.9085